Familial Hypercholesterolemia Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Familial Hypercholesterolemia Epidemiology Forecast Report Coverage

Expert Market Research's “Familial Hypercholesterolemia Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of familial hypercholesterolemia. It projects the future incidence and prevalence rates of familial hypercholesterolemia cases across various populations. The study covers age, gender, and type as major determinants of the familial hypercholesterolemia population. The report highlights patterns in the prevalence of familial hypercholesterolemia over time and projects future trends based on multiple variables.

Familial Hypercholesterolemia Understanding: Disease Overview

Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder caused primarily by mutations in the LDL receptor (LDLR) gene, the apolipoprotein B (APOB) gene, or the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, all of which impair the normal clearance of LDL cholesterol from the bloodstream. As a result, affected individuals maintain persistently elevated LDL-C levels from birth, leading to early and progressive atherosclerotic plaque formation. Clinical manifestations include tendon xanthomas, corneal arcus, xanthelasma, and a family history of premature cardiovascular disease.

Familial Hypercholesterolemia Epidemiology Perspective

The familial hypercholesterolemia epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the familial hypercholesterolemia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for familial hypercholesterolemia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Sabina O. Beheshti et al., 2020, an analysis of more than 11 million subjects across 104 studies estimated the global prevalence of heterozygous Familial Hypercholesterolemia (FH) at approximately 1 in 313 individuals (0.32%). The prevalence is significantly higher among individuals with ischemic heart disease and severe hypercholesterolemia.
• As per Pengwei Hu et al., 2020, the overall prevalence of heterozygous Familial Hypercholesterolemia is about 1 in 311 people worldwide, making it one of the most common inherited metabolic disorders. This condition occurs across diverse populations and is more frequently observed among patients with atherosclerotic cardiovascular disease.
• According to the World Heart Federation, Familial Hypercholesterolemia affects nearly 1 in 311 people globally, representing around 25 million individuals. Homozygous Familial Hypercholesterolemia is extremely rare, affecting roughly 1 in 300,000 people, and fewer than 5% of cases are accurately diagnosed, highlighting significant underdiagnosis worldwide.
• According to the Centers for Disease Control and Prevention (CDC), untreated Familial Hypercholesterolemia substantially increases early cardiovascular risk. Approximately 30% of women experience heart attacks by age 60, while 50% of men experience heart attacks by age 50, demonstrating pronounced age-related and gender-based differences in disease outcomes.
• As per Marianne Klevmoen et al., 2023, the prevalence of heterozygous Familial Hypercholesterolemia is estimated at 1 in 313 in the general population, 1 in 31 among individuals with ischemic heart disease, and 1 in 15 among those with premature ischemic heart disease, with similar prevalence observed in both men and women.

Read more about this report - Request a Free Sample

Country-wise Familial Hypercholesterolemia Epidemiology

The familial hypercholesterolemia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Familial hypercholesterolemia (FH) shows a notable epidemiological burden across major healthcare regions, emphasizing the need for improved detection and surveillance. According to J.P.S. Sawhney et al., 2024, the global prevalence of heterozygous FH is estimated at approximately 1 in 200–250 individuals. In India, FH is estimated to affect nearly 5 million individuals, with a study of 4,000 participants reporting a prevalence of 1 in 1,000 (0.1%) for definite FH, while the India Heart Watch study across 11 cities found suspected FH prevalence ranging from 1:125 to 1:450 in urban populations. According to Christopher Page et al., 2023, the prevalence in the United Kingdom is estimated at about 1 in 250 individuals. In Germany, the prevalence of genetically confirmed FH was reported at 0.31% according to Riccio et al., 2025. Additionally, according to J.P.S. Sawhney et al., 2024, FH prevalence is significantly higher in high-risk populations, reaching approximately 10% among young coronary artery disease patients in the United States and 14.7% in Australia, reflecting similar trends in developed cardiovascular care settings. Collectively, these regional data highlight the substantial yet underdiagnosed epidemiological burden of FH.

Familial Hypercholesterolemia: Treatment Overview

Treatment of familial hypercholesterolemia is lifelong and aims to substantially lower LDL-C levels to reduce the risk of premature ASCVD events. High-intensity statin therapy remains the cornerstone of FH management, intending to achieve at least a 50% LDL-C reduction from baseline. Combination therapy with ezetimibe is recommended when LDL-C targets are not met with statins alone. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, including evolocumab (Repatha) and alirocumab (Praluent), represent a major therapeutic advance, providing 60% to 70% additional LDL-C reduction when added to maximally tolerated statin therapy. Inclisiran, a small interfering RNA (siRNA) agent targeting PCSK9 with a twice-yearly dosing schedule, offers an alternative for patients requiring long-term lipid management. For severe homozygous FH, lomitapide and LDL apheresis remain the important therapeutic options. Emerging agents targeting lipoprotein(a) and novel gene therapy approaches are under active investigation for refractory cases. Cascade screening of first-degree relatives remains the most impactful public health intervention for early identification and treatment initiation.

Key Questions Answered

• What are the key findings of familial hypercholesterolemia epidemiology in the 8 major markets?
• What will be the total number of patients with familial hypercholesterolemia across the 8 major markets during the forecast period?
• What was the country-wise familial hypercholesterolemia epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of familial hypercholesterolemia patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of familial hypercholesterolemia during the forecast period of 2026-2035?
• What are the currently available treatments for familial hypercholesterolemia?
• What are the disease risks, signs, symptoms, and unmet needs of familial hypercholesterolemia?

Scope of the Familial Hypercholesterolemia Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of familial hypercholesterolemia based on several factors.
• Familial Hypercholesterolemia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The familial hypercholesterolemia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Familial Hypercholesterolemia Drug Pipeline Analysis Report

Cardiovascular Drugs Market

Cardiovascular Devices Market